Syngene shares surged nearly 17% on Thursday despite reporting a 20% year-on-year decline in FY26 profit to ₹380 crore before exceptional items. According to reports from The Economic Times, the stock rallied to ₹505.60 in afternoon trading, with the shares gaining over 17% in one week and nearly 29% in one month. However, the stock remains down nearly 23% in 2026 so far, with a market capitalisation of nearly ₹20,280 crore. The company's Q4 FY26 results showed contrasting performance with revenue from operations growing 2% year-on-year to ₹1,037 crore compared to ₹1,018 crore in Q4 FY25, but operating EBITDA declined 12% to ₹303 crore, resulting in margin compression to 29% from 34% in the corresponding quarter last year.
For the full year ended March 31, 2026, Syngene delivered revenue growth of 3% to ₹3,739 crore compared to ₹3,642 crore in the previous year. However, operating EBITDA margin compressed to 25% from 29% in the previous year, while profit after tax before exceptional items fell 20% to ₹380 crore. The company's Q4 FY26 results showed revenue from operations growing 2% year-on-year to ₹1,037 crore compared to ₹1,018 crore in Q4 FY25. However, operating EBITDA declined 12% to ₹303 crore, resulting in margin compression to 29% from 34% in the corresponding quarter last year. The net profit for Q4 FY26 dropped from ₹183 crore in the fourth quarter of the previous financial year, but showed a multi-fold increase from ₹15 crore reported in Q3 FY26. The net profit for the reported quarter included a gratuity re-measurement credit of ₹20 crore arising from revised labour codes, and ₹25 crore exceptional loss related to termination benefits extended to employees.
According to reports from The Economic Times, Kiran Mazumdar-Shaw transitioned from Non Executive Chairman to Executive Chairman from April 1 onwards, expressing satisfaction with taking the role at a pivotal moment in the company's growth journey. The company announced that Siddharth Mittal has been appointed as Managing Director and CEO, effective from July 1, 2026, for a five-year term. Mittal previously served as Managing Director and CEO of Biocon. Additionally, Maninder Kapoor Puri will take over as Chief Human Resources Officer from May 1 onwards, having previously led the HR function at Biocon. The company also appointed Abhijit Zutshi as Chief Commercial Officer from May 1, 2026. Executive Chairperson Kiran Mazumdar-Shaw highlighted the company's resilient business model, stating that Syngene's diversified end-to-end platform from discovery to manufacturing provides strategic agility in navigating current market realities. The company continues investing in AI and digital capabilities to enhance client value creation.
As reported by The Economic Times, Peter Bains, Managing Director and CEO, stated that Syngene's full-year revenue from operations grew 3%, with an EBITDA margin of 25% performance in line with revised full-year guidance. The company generated ₹521 crore of cash during the year, post capex investment, strengthening its balance sheet. Deepak Jain, CFO, noted that Q4 reported growth at 2% and 13% sequentially reflects ongoing product impact in the largest biologics customer, resulting in full-year growth of 3%. CFO Deepak Jain attributed the margin compression to the biologics customer impact and additional operating costs from bringing the new biologics manufacturing facility online. Managing Director and CEO Peter Bains noted that performance aligned with revised full-year guidance, with underlying business showing steady momentum despite impact from a single large-molecule biologics client.
For the full year ended March 31, 2026, Syngene delivered revenue growth of 3% to ₹3,739 crore compared to ₹3,642 crore in the previous year. However, operating EBITDA margin compressed to 25% from 29% in the previous year, while profit after tax before exceptional items fell 20% to ₹380 crore. The company's board recommended a final dividend of ₹1.25 per equity share for FY26, with the record date fixed as Friday, June 26, 2026. The dividend will be paid within 30 days from shareholder approval, with the 33rd Annual General Meeting scheduled for July 29, 2026. The company also approved the appointment of S. R. Batliboi & Associates LLP as statutory auditors for a five-year term from 2026-2031.
